Anxiety Linked to Increased Risk for Acute Exacerbations in Older Adults with COPD
Nearly 20% of an older cohort with COPD reported anxiety that was subsequently associated with more severe symptoms and acute exacerbations.
Mental Health Risks Persist for Years Following Severe Maternal Morbidity in Pregnancy
Severe maternal morbidity during pregnancy increases the risk for mental health hospitalization or ED visits for as long as 13 years, a Canadian study found.
The 10 States with the Largest ↑ Increase in Diabetes Dx & 5 States with the Largest ↓ Decrease
Diagnoses of diabetes increased the most in South Dakota between 2018 and 2021 at 18.45%; diagnoses decreased the most in Hawaii at 15.61%. More, here.
Final USPSTF Recommendation on Breast Cancer Screening Lowers Starting Age from 50 to 40 Years, Highlights Racial Disparities
The USPSTF decision to reduce age of initiation is based on increasing rates of breast cancer in younger women; the group vows more research on higher mortality for Black women.
Cardiovascular-Kidney-Metabolic (CKM) Syndrome Affects Nearly All US Adults
The majority of the US adult population meets criteria for subclinical CKM syndrome indicating "an urgent need for population-wide risk reduction measures."
The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD
Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.
Dermavant: FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Adults, Children with Atopic Dermatitis
The FDA PDUFA date for taparinof cream 1% will be during the 4th quarter, Dermavant said, with approval based on ADORING phase 3 clinical trial data.
A MASLD Mantra to Practice By: Screen, Stage, Treat
Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.
Merck's 21-Valent Pneumococcal Vaccine Delivers More Positive Phase 3 Data in Advance of 6-17-2024 PDUFA Date
In STRIDE 10, V116 was superior to PPSV23 in adults aged ≥50 years and naive to pneumococcal vaccine for 8 of 9 serotypes unique to Merck's investigational shot.
The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.
Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.
FDA Approves Second Generic OTC Naloxone Nasal Spray to Reverse Opioid Overdose
The newest generic OTC nonprescription naloxone hydrochloride nasal spray provides additional access to the lifesaving treatment, at potentially lower cost.
American Liver Foundation Announces First Federally-Funded Research on MASLD
The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.
FDA Approves First New Antibiotic in Decades for Uncomplicated UTI
Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.
Food vs Medicine for IBS: Dietary Measures First, New Study Suggests
More participants consuming either of 2 common IBS dietary regimens experienced significant and sustained symptom relief vs those given pharmacotherapy.
The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD
Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.
The Price of the US Health Care Affordability Crisis: High Anxiety, Skipped Care, Failing Health
To cover a medical bill, more than half of those surveyed would downsize a home, 75% would take on a second job; more than 1/3 had already skipped care due to costs.
Treatment by Female Physicians Linked to Lower Mortality, Hospital Readmissions
Treatment by female physicians resulted in better 30-day outcomes for male and female patients, but the benefit was significantly greater for the women.
Maternal Vascular Indices, Biomarkers at 36 Week's Gestation Predict Preeclampsia, New Study Concludes
Increased arterial stiffness and elevated central BP are among factors researchers found to have strong discriminatory value for PE at term and postpartum.
Vedolizumab (Entyvio) SC Approved for Maintenance Therapy in Adults with Moderately to Severely Active Crohn Disease
Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.
ACP Recommends SGLT2i, GLP1 RA After Metformin to Manage Cardiorenal Comorbidities in Adults with Type 2 Diabetes
Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.
After the CLEAR Outcomes Trial, ASCVD Risk Reduction Remains a Global Challenge, PI Nissen Says
The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.
Bempedoic Acid Should be In Everyone's CVD Prevention Toolbox, According to Steven Nissen, MD
Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.
Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD
Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.
Steven Nissen, MD, Discusses the "Sweet Spot" for Bempedoic Acid Among Non-Statin Therapies
The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.
How the CLEAR Outcomes Trial Made CV Risk Reduction History, with Lead Investigator Steven Nissen, MD
Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.
Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission
Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.
Tezepelumab for COPD Moves into Phase 3 Planning
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA
The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort
Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.